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PATTERNS OF ANTIDEPRESSANT PRESCRIPTIONS : I 
ACUTE PHASE TREATMENTS 
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ABSTRACT 
Although depression is an eminently treatable condition, inadequate pharmacotherapy is far 
too common. Lack of uniform standards of care across different settings characterises psychiatric 
practice in a developing country like India. But, there have hardly been any attempts at assessing 
the standards of care being delivered. A case note study was carried out of patients attending a 
general hospital psychiatric unit with depression, over a one year period, to evaluate the nature and 
adequacy of antidepressant therapy. Prescribing patterns in 108 cases fulfilling the selection criteria, 
were examined. The sample consisted mainly of young to middle aged patients, predominantly 
female, with moderately severe depressive episodes. Antidepressants were prescribed universally 
with TCAs (mainly Imipraminc), followed by Fluoxetine being the most common drugs used. 
Pharmacotherapy was often found to be deficient in several areas such as, starting doses, rate of 
increase in dose, maximum doses used, dose titrations, duration of treatment, change of drugs, 
recording of side effects and compliance etc. Results regarding norms for adequate doses and 
periods of treatment before switching drugs, for the kind of patients included in this study, were 
unclear, and need to be explored further. Inadequate treatment can have a number of adverse 
consequences, hence some guidelines for minimum standards of care while undertaking 
antidepressant treatment need to be formulated for India and other developing countries, as none 
exist at present. 
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Depressive episodes when accurately Depression (CDS) underlined this by showing 
diagnosed, respond reasonably well to treatment that both prior to induction, and while in the study 
(Richelson, 1993) Despite this well-known fact, for several years, about one third to half of the 
under-treatment of depression is rife, perhaps patients received low levels of antidepressant 
partly due to difficulties in detecting and treatment (Keller et al., 1986). 
accurately diagnosing cases suitable for The reasons for under-treatment are not 
pharmacotherapy. However, sufficient evidence exactly clear, but lack of compliance, anticipation 
exists to suggest that a number of correctly of side effects and unawareness of the need to 
diagnosed patients receive inadequate levels of continue treatment even when well, are some 
somatotherapy or psychotherapy (Quitkin, 1985). of the likely causes on the patient's part. Of more 
Under-treatment is common in all settings, concern, is the tendency of some clinicians to 
including psychiatric facilities (Goethe et al., prescribe low doses,-or to decrease dose levels 
1988). primary care (Donoghue & Tylee, 1996), when minor side effects occur, and to desist from 
and in specialities other than psychiatry further efforts at achieving a therapeutic dose 
(Fauman, 1980). Treatment data gathered during (Quitkin,1985). The consequences of inadequate 
the Collaborative Study of Psychobiology of treatment are not hard to predict and include high 
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risks of chronicity, recurrence, and relapse, as 
well as being labelled 'treatment resistant' (Keller 
etal., 1986; Keller, 1994). 
Hardly any Indian studies have looked at 
the quality of psychiatric care being delivered, 
in a country where psychiatric practice is 
characterised by marked variability across 
different treatment settings, and a genuine need 
for establishing uniform standards of care. It was 
thus decided to examine the nature and 
adequacy of antidepressant prescribing practices 
in our unit. The aim was to gather data as a first 
step towards setting down certain minimum 
standards required to undertake treatment with 
antidepressants in India. 
MATERIAL AND METHOD 
The study was carried out in the 
psychiatric unit of a large multi-speciality 
teaching hospital, the Nehru Hospital of the 
Postgraduate Institute of Medical Education and 
Research, Chandigarh. 
All patients attending the unit are initially 
screened by a psychiatrist at the' Walk -in' clinic 
level, and drug treatment often started. 
Subsequently, a detailed evaluation is done by 
a trainee psychiatrist under supervision of a 
consultant. Treatment plans are charted out, and 
patients are then followed-up in the outpatient 
clinic, unless admitted, or referred elsewhere. 
Case notes for the year 1996 were 
scanned for all cases of depression. Those, 
which fulfilled the selection criteria, were included 
for purposes of the study. The data pertaining to 
antidepressants was then extracted from the 
note6 and entered onto the preset proforma. 
Selection criteria : cases were included if they 
were diagnosed to have either: - a) depressive 
episodes of mild, moderate, or severe type; with 
or without somatic symptoms (ICD-10), or 
b) recurrent depressive disorder with similar 
current episodes. 
Cases were excluded if they had: - a) bipolar 
depression; b) any comorbid diagnoses; 
c) psychotic symptoms; d) chronic episodes (> 
2 years); e) organic brain syndromes; f) 
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substance abuse; g) associated physical 
problems judged to be interfering with 
antidepressant treatment and h) follow up period 
less than 6 weeks. 
A deliberate attempt was thus made to 
include relatively 'uncomplicated' cases of 
depression by excluding secondary depressions, 
chronic episodes, and comorbid conditions. 
Although this restricted the scope of the study, it 
was felt that proper judgements about adequacy 
of treatment could only be made after ruling out 
these confounding variables. 
Criteria for adequacy' of antidepressant 
treatment were derived from standard guidelines 
and results of original studies. These are included 
in the appendix. 
RESULTS 
Only the results pertaining to acute phase 
treatments are presented here. 
Size of the sample: In all 108 case notes fulfilling 
the selection criteria were examined. 
Selected demographics : Majority of the sample 
were females (58%), half of them aged between 
20-39 years, and a little more than a quarter 
(26%) in the age range of 40-49 years. Families 
were divided into those with a monthly income 
of less than Rs. 3000 per month, and those with 
incomes at or above this figure. The rationale 
was that the average cost of some of the more 
expensive drugs would be about 5% of Rs.3000, 
thus placing a significant financial burden on 
families earning less than this. The sample had 
more families (56%) with incomes of Rs.3000 
per month, or more. 
Clinical profile: 
Treatment setting : Most patients (95%) received 
treatment on an outpatient basis, perhaps 
reflecting the less severe nature of their 
depression. Five patients were admitted, 4 of 
them for ECT. They were subsequently seen in 
the outpatient clinic. 
Length of follow up: Average length of follow up 
was 9.5 (s.d. 5.3) months; range 2 - 21 months. 
Average number of visits during the acute phase 
of treatment was 6.1 (s.d. 3.5). 
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TABLE 1 
DIAGNOSTIC DISTRIBUTION OF THE SAMPLE * + 
1. Depressive episodes (n = 75) 
Mild without somatic symptoms 3 
Mild with somatic symptoms 3 
Moderate without somatic symptoms 10 
Moderate with somatic symptoms 36 
Severe without psychotic symptoms 23 
2. Recurrent depressive disorder (n = 33) 
Mild without somatic symptoms 2 
Moderate without somatic symptoms 8 
Moderate with somatic symptoms 15 
Severe without psychotic symptoms 8 
* Total number of cases-108 
+ ICD-1. diagnoses 
Index episode diagnosis 
mild depression - n = 8 (7%) 
moderate depression - n = 69 (64%) 
severe depression - n = 31 (29%) 
Diagnostic distribution : The diagnostic break 
up of the sample is shown in tabie-1. Moderate 
depression with or without somatic symptoms 
was by far the most frequent diagnosis (64%), 
for the index episode. 
Pre-treatment duration : The average duration 
of the index episode prior to seeking treatment 
was 4.7 (s.d. 4.6) months, with a wide range from 
1 week to 18 months. Pre-treatment duration was 
less than 3 months in 59% of the cases, a further 
34% had a duration between 3-12 months. 
Durations of more than a year were rare (6.5%) 
Overall, the sample therefore consisted mainly 
of youiig to middle aged patients, mostly female, 
with moderately severe episodes of depression, 
which were of relatively short durations. 
Treatment profile : 
Modes of antidepressant treatment: Only data 
pertaining to the acute phases of treatment are 
presented here (table 2). 
Sixty nine patients (64%) received only a 
single antidepressant. Antidepressants were 
changed once in 26 cases (24%), and in 13 
patients (12%) a third or a fourth drug was used. 
Two antidepressants were used in conjunction 
in 19 cases (18%). In most of these patients 
Trazodone was the additional drug, used mainly 
for its sedative properties, in doses of 25-100 
mg at night. 
Dose considerations: 
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TABLE - 2 
MODES OF ANTIDEPRESSANT TREATMENT * 
LTCAs** 
Imipramine 
Dotheipin 
Amitriptyline 
Nortriptyline 
Cloimipramine 
Doxepin 
Amineptine 
2. Fluoxetine 
3. Others 
Mianserin 
Amoxapine 
Trazodone 
4. ECT 
5. Lithium + 
50 
18 
12 
8 
2 
1 
1 
47 
11 
6 
1 
5 
1 
(46%) 
(44%) 
* Although total number of cases was 108, total number of 
'treatment episodes' was more, because more than one 
treatment was used in a proportion of cases. 
- All cases received antidepressants. 
** 92 patients (85%) received a TCA at some point during 
their treatment. 
+ Lithium was used primarily to treat a hypomanic switch. 
Starting and maximum doses : A total of 144 
episodes of treatment with antidepressants were 
analysed. The starting and maximum doses were 
recorded for each episode, (table - 3). 
'Rate of hike': The time taken to attain maximum 
doses was less than 3 weeks in most (n=81; 56%) 
of the treatment episodes, but in 21% (n=30) it 
took 3-6 weeks, and in 23% (n=33) even longer. 
In 57 episodes (40%) antidepressants were 
started at their maximum doses. 
'Dose titration' : From the data available a 
judgement was also made whether doses were 
adjusted during the course of treatment 
depending upon response, or emergence of side 
effects. The proportion in which such 'dose 
titrations' were made (n = 79; 55%) exceeded 
those in which such attempts were absent (n = 
65; 45%), but only by a small margin. 
Duration of treatment : Antidepressants were 
prescribed at maximum doses for more than 6 
weeks in about three quarters (73%) of the 
treatment episodes. Thus, even after excluding 
episodes where the dose had to be reduced 
because of side effects or patient drop out, a 
substantial proportion (21%) had received 
maximum doses for less than 6 weeks. S. CHAKRABARTI & P. KULHARA 
TABLE - 3 
STARTING AND MAXIMUM DOSES OF ANTIDEPRESSANTS 
1. TCAs* IMI. 
( n = 43) 
Starting doses (mg/ day) 
25-50 6 
75 21 
>100 16 
Maximum doses (mg / day 
<150 16 
150 14 
>150 13 
2 Fluoxetine (n = 47) 
Starting doses (mg/ day) 
20 
40 
3. Mianserin (n = 9) 
Starting doses (mg/day) 
10-30 
>30 
4. Amoxapine ( n = 6) 
Starting doses (mg/day) 
<100 
>100 
DOT. 
(n=17) 
3 
12 
2 
7 
6 
4 
34 (72 %) 
13(28%) 
8 
1 
2 
4 
ATN. 
(n = 9) 
5 
3 
1 
7 
1 
1 
NT. 
(n = 10) 
-
4 
6 
4 
4 
2 
CLOIMI. 
(n = 2) 
-
1 
1 
2 
-
-
DOX. 
(n=1) 
-
1 
-
1 
-
-
Maximum doses (mg/ day) 
20 
40 
60 
16 (34%) 
25 (53% ) 
6 (13%) 
Maximum doses (mg/ day) 
10-30 
>30 
5 
4 
Maximum doses (mg/ day) 
<100 
>100 
2 
4 
TOTAL# 
( n = 82) 
14 (17%) 
42 (51%) 
26 ( 32%) 
37 (45%) 
25 (30%) 
20 (24%) 
- All TCA doses in imipramine equivalents 
- This is the no of treatment episodes, different from the no. of cases; some episodes have not been 
included in this analysis _ 
IMI - Imipramine, DOT - Dotheipin; ATN - Amitriptyline', NT - Nortriptyline'; 
CLOIMI- Cloimipramine; DOX - Doxepin 
Response considerations : Data regardiag the 
type of response, time to remission, and dose-
response relationships is shown in table - 4. Since 
no structured assessments were used 
judgements about response had to be made 
somewhat arbitrarily. If the notes indicated that 
the patient was ' euthymic' or 'asymptomatic' 
on two occasions a month apart, the episode 
was judged to have remitted. Assessments of 
improvement in mental state were also made 
from the notes 
Change of antidepressant: In the 39 cases where 
drugs had been switched, all antidepressant 
treatment episodes were analysed on two 
parameters, viz reasons for change and 
adeguacy of treatment. In a guarter of the sample 
reasons for change of drug were not clear After 
excluding changes due to side effects or cost, 
antidepressants were found to be used in 
inadeguate doses, or for inadeguate periods, on 
most occasions (67%), before they were 
changed. ECT was only used in one such case 
and augmentation with lithium was non-existent. 
Recording of side effects and compliance : 
Compliance with treatment was not recorded at 
all in 64% cases, in 34% it was recorded for less 
than half of the follow-up visits. The recording 
of side effects was not done in 58% of the cases. 
In about a third (36%) of these cases side effects 
were recorded on less than half the occasions. 
Cost of the drug ; Among the demographic 
parameters only family income emerged as a 
significant determinant of drug choice. 
Fluoxetine was prescribed as a first choice 
antidepressant in 14 families from a higher 
income bracket (Rs.3000 per month or more), 
as opposed to only 7 patients with family incomes 
less than this, who prescribed were this drug to 
start with On the other hand more patients from 
lower than higher income families received 
Imipramine (19 v/s 12). These differences were 
significant (X
2 = 3.91, df=1; p < 0.05). 
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TABLE 4 
RESPONSE PATTERNS # & TIME TO REMISSION # 
TCAs 
Response 
Number + (82) 
Remitted 37 
Improved 22 
No response 23 
Time to remission 
Number++ (37) 
0-6 weeks 14 
6-12 weeks 11 
>12 weeks 12 
Dose v/s response 
TCAs* 
( n = 82) < 
Remitted or improved 
No response 
Fluoxetine" 
( n = 47) 20 
Remitted or improved 
No response 
FLX. 
(47) 
21 
11 
15 
(21) 
6 
7 
8 
150 mg/day 
29 
13 
mg/day 
9 
6 
Others Total 
(15) 
5 
7 
3 
(5) 
5 
(144) 
63 (43%) 
40 (28%) 
41 (28.5%) 
(63) 
25 (40%) 
18(29%) 
20 (32%) 
> 150 mg/day 
33 
7 
40-60 mg/day 
23 
9 
# Response is to maximum doses of antidepressants &time 
to remission is the time taken for the depressive episode 
to remit after maximum doses have been achieved 
+ Number of treatment episodes; ++ Number of treatment 
episodes which ended in remission 
- FLX - Fluoxetine; - Others - include Mianserin & 
Amoxapine 
' X-' = 2.01;df=1;NS 
"X
2 = 0.66;df=1;NS 
DISCUSSION 
A number of confounding variables make 
it difficult to interpret and draw conclusions from 
such retrospective studies. Indicators of outcome 
are usually crude as structured assessments are 
not used routinely. Records can be incomplete, 
often not accurately reflecting the setting in which 
treatment decisions were taken. Some 
information is simply not available. To avert 
some of these problems it was decided to focus 
mainly on data that was relatively unambiguous 
eg type of drug used, dose and duration of 
treatment etc Further, the sample was 
deliberately chosen to exclude confounders such 
as diagnosis (psychotic or bipolar depression) , 
comorbidity (dysthymia, physical illness, 
substance abuse) , and chronicity, which could 
have influenced treatment decisions. This, 
despite restricting the scope of the study lends 
more credence to its findings. 
The results show that antidepressants 
were used universally. Though TCAs (mainly 
Imipramine) were used most frequently, the 
number of Fluoxetine prescriptions was almost 
similar to Imipramine. This parallels national 
trends and represents a tremendous increase in 
prescriptions since the drug was first introduced 
in India in the early nineties (Andrade, 1997). 
This is perhaps a good indicator of the safety, 
efficacy, and acceptability of Fluoxetine, the only 
SSRI available in India, till recently. 
Cost of the drug (not age or sex of the 
patient) was found to be a significant determinant 
of its choice. Imipramine is less expensive than 
Fluoxetine, and is dispensed by the hospital 
pharmacy free of cost. Thus, it was not surprising 
that patients prescribed Fluoxetine mostly came 
from a higher income bracket, while the reverse 
was true for Imipramine. The slight higher 
income bias of the sample must, however, be 
noted. 
The practice of antidepressant therapy was 
deficient in several respects. Although drugs were 
usually started in low doses and gradually 
increased over a period of two to three weeks as 
recommended (Laurence & Bennet, 1992), in a 
substantial proportion starting doses were either 
too high, or the rate of hike too slow. Moreover, 
there were many instances of starting treatment 
with the maximum dose. Dose adjustments are 
necessary during the course of therapy, depending 
on response and emergence of side effects. 
However, such dose titrations were neglected in 
about half of the treatment episodes. 
Adequacy of antidepressant treatment is 
usually defined in terms of the dosage of 
medication used and the duration of treatment. 
General consensus suggests that an adequate 
dose of an antidepressant is 150 mg/day 
Imipramine equivalents or more (Quitkin, 1985; 
Clinical Resource and Audit Group, 1993), 
although doses higher than this have also been 
recommended (Goethe etal, 1988) Inthisstudy, 
maximum doses of TCAs were less than 150 mg/ 
day in 45% of the treatment episodes. Doses of 
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Fluoxetine appeared adequate, although creating 
dose equivalencies is difficult, especially for 
SSRIs where dose-response relationships are less 
clear (Schatzberg, 1995) A surprising finding was 
that although the commonly recommended dose 
of Fluoxetine is 20 mg/day, two- thirds of the 
patients on this drug had received doses in the 
range of 40-60 mg/day. 
Why were antidepressants, especially 
TCAs, used in such inadequate doses? The 
reasons are not clear, though one could be the 
differing dose requirement of this particular 
population, which perhaps belonged to the milder 
end of the spectrum. Moreover, a number of 
studies have now demonstrated that Asians 
usually require lower doses of psychotropics to 
achieve similar degrees of response (Kuruvilla, 
1996). Two aspects of the data are worth noting 
in this regard. Firstly, despite such ' inadequate 
doses', 72% of the episodes had a favourable 
outcome, comparing well with response rates 
reported in literature (Richelson, 1993). Further, 
for TCAs the number of treatment responsive 
episodes were not significantly different between 
the two dose conditions, i.e. less than or greater 
than 150 mg/day of Imipramine equivalents. The 
number of favourable outcomes was more with 
higher doses (40-60 mg/day) of Fluoxetine, but 
these differences were also not significant. 
Without reading too much into the results, it is 
possible to conclude that further dose-response 
studies are needed in this population to 
determine what constitutes an adequate dose 
of a particular antidepressant. 
How long should antidepressants be used 
before a decision is made to switch drugs 
because of non-response? Opinions are divided 
with some authors suggesting that six to eight 
weeks is adequate (Szabadi & Bradshaw, 1995) 
and others proposing periods of 12 weeks or 
longer (Potale & Gogates, 1994). The problem 
becomes more complex if there is only partial 
response to treatment About three fourths of 
this sample had received treatment for more than 
6 weeks However, only 38% of the sample 
remitted within 6 weeks of attaining the 
maximum dose, 29% took up to 12 weeks, and 
32% even longer, to remit. This data thus 
suggests that a substantial proportion of cases 
on antidepressants take longer than 6 weeks to 
remit. Although definite conclusions are again 
not possible it seems preferable to persist with 
one drug for longer than 6 weeks, especially in 
cases of partial response. 
Cases, which required one or several 
changes in drugs also, revealed some flaws in 
the current prescribing practices. Although non-
response was recorded as the main reason for 
switching antidepressants, drugs were often used 
in inadequate doses, or for inadequate periods 
of time, before a change was made. Changes 
from one agent to another of the same family 
(e.g. from Dotheipin to Imipramine) were made 
in over a quarter (28%) of such cases, which 
goes against the standard practice of using a 
drug from a different group in such instances 
(American Psychiatric Association Work Group 
on Major Depressive Disorders, 1993). Since 
these cases would be considered difficult to treat 
or be labelled 'treatment- refractory', these 
findings lend further support for the belief that, 
more often than not, such problems are a result 
of inadequate treatment (Quitkin, 1985). 
Side effects often determine the choice of 
a particular agent (Mcpherson & Robson, 1994), 
and several studies suggest that about half the 
patients become non-compliant at some point 
during treatment (Clinical Resource and Audit 
Group, 1993). Given these facts, the scant attention 
paid to noting down side effects, or compliance 
with treatment, also raises some concern. 
The trend towards under-treatment of 
depression highlighted by this study is 
depressingly familiar. It was not possible to 
explore the reasons for these deficiencies in 
practice, which is a major limitation of this study. 
Nevertheless, the results suggest that the norms 
regarding adequate doses and periods of 
treatment before switching drugs, could be 
different for such patient populations. There is 
thus a need for further prospective studies to 
determine the mnimum standards of care for 
drug treatment of depression across various 
settings in our country. 
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| The sample was fairly representative of the 
• bulk ofdepressed patients being treated in general 
hospital psychiatric units in this country. Since 
these units form the backbone of psychiatric 
services in India (Venkoba-Rao, 1986), the results 
. would probably be applicable to a large number 
of patients using the psychiatric facilities. 
< However, the findings cannot be generalised to 
I other settings such as primary care, or mental 
; hospitals, and the size of the sample is perhaps 
i too small to make any definite predictions about 
I the treatment being received by depressed 
patients in all general hospital units. Future 
studies, which address these issues, will hopefully 
provide the foundations of rational and uniform 
standards of care, with regard to antidepressant 
treatment in India. 
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APPENDIX 
CRITERIA FOR ADEQUATE
1 ANTIDEPRESSANT 
TREATMENT IN THE ACUTE PHASE + 
• Starting doses 
50 -75 mg/day of Imipramine or its equivalent 
10-20 mg/day of Fluoxetine 
• Adequate (full) doses 
at least 150 mg/day of Imipramine or its equivalent 
at least 20 mg/day of Fluoxetine 
• Rate of hike' 
a maximum period of 2-3 weeks between starting 
drug treatment and reaching full doses 
• Dose titration' 
dose of drug needs to be titrated depending on 
response obtained and emergence of side effects 
• Duration of treatment 
minimum of 6 weeks with one drug at full doses 
• Switching drugs 
in case of non-response to a drug used in adequate 
doses and for adequate duration, a switch to a 
different class of agents should be made, reasons 
for switching should be clearly recorded 
• Recording 
during each follow up visit effort should be made 
to enquire about and record compliance with 
treatment and side effects if any 
+ these criteria have been derived from the following -
• American Psychiatric Association Work Group on Major 
Depressive Disorder. 1993 
• Clinical Resource and Audit Group. 1993; 
• Laurence and Bennet. 1992. 
• Scnatzberg.1995 
• Donovan et al. 1994 
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